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Introduction: Patients with systemic lupus erythematosus (SLE) have a decreased ability to clear cell remnants
and multiple deficiencies in the ability to degrade cellular chromatin have been linked to the disease. Since the
discovery of neutrophil extracellular traps (NETs), a renewed interest has been sparked in this field of research
with multiple studies reporting a decreased ability of patients with SLE to degrade NETs. In this study we extend
these findings by investigating the ability of patients with SLE to degrade chromatin from multiple clinically
relevant sources.
Methods: We use flow cytometry in combination with NET degradation and DNA zymogram assays to investigate the
ability of sera from SLE patients to degrade chromatin from three different sources of DNA such as NETs, apoptotic and
necrotic cells. This ability was further associated with clinical manifestations.
Results: We found that 61 % of the patients had an affected degradation of at least one chromatin source. Further,
degradation of NETs correlated with degradation of chromatin from secondary necrotic cells but not with degradation
of chromatin from primary necrotic cells. Patients who fail to degrade several forms of DNA more often display
anti-nuclear and nephritic involvement whereas this is not observed in patients with decreased ability to degrade
chromatin from primary necrotic cells.
Conclusions: The majority of patients with SLE has a decreased ability to degrade chromatin from clinically
relevant sources. This decreased ability is further reflected in their clinical presentation.Introduction
Patients with the autoimmune disorder systemic lupus
erythematosus (SLE) exhibit, for yet non-clarified reasons,
a decreased ability to degrade DNA. The phenomenon
was first observed in the 1960s [1], and has recently
regained new interest with the discovery of neutrophil
extracellular traps (NETs) [2]. NETs consist of chromatin
covered with antimicrobial proteins and constitute a can-
didate autoantigen target in SLE. SLE is characterized by
an autoimmune reaction against many nuclear antigens
historically proposed to originate from apoptotic cells that
are not properly cleared [3]. DNA in various forms is de-
graded by specific nucleases where DNase-I is the main* Correspondence: anna.blom@med.lu.se
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leased into serum. The role of DNase-I in SLE received at-
tention when it was discovered that the presence of a
DNase-I inhibitor correlated with levels of nuclear auto-
antibodies [1] and that SLE patients had decreased serum
nuclease activity [4]. Attempts were subsequently made to
restore the activity by infusion of recombinant DNase-I
but without reaching a sufficient serum concentration to
lead to clinical improvements [5]. Recently, it was con-
firmed that sera from a subgroup of SLE patients do not
degrade NETs [6, 7].
Although NETs pose a highly interesting target in SLE,
other chromatin sources like apoptotic and necrotic cells
should not be forgotten. The importance of serum nu-
cleases for the degradation of apoptotic and necrotic cells
has been studied previously and it appears that this process
is dependent on additional cofactors, such as complement
C1q [8], serum amyloid P [9], factor VII-activating proteasee is distributed under the terms of the Creative Commons Attribution 4.0
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Table 1 Patient characteristics according to American College
of Rheumatology (ACR) criteria
ACR criteria Number of patients (%)
Malar rash 44 (66.7)
Discoid rash 18 (27.3)
Photosensitivity 42 (63.6)




Neurological disorder 3 (4.5)
Hematological disorder 37 (56.1)
Immunological disorder 51 (77.3)
Anti-nuclear antibodies 66 (100)
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chromatin. These cofactors are thought to open the nor-
mally condensed chromatin structure by displacing histone
H1. NETs consist of decondensed, open chromatin and
therefore degradation is not dependent on such cofactors.
In our previous study we instead observed that C1q inhib-
ited degradation of NETs and hypothesized this to be a
trade-off for opsonisation [6], which was later confirmed
by another group [12]. The current literature hence pro-
poses that multiple factors are important in the degrad-
ation of DNA depending on the source and nature of the
chromatin. Patients with SLE have been described to have
a decreased DNase activity [4] but how that relates to dif-
ferent forms of DNA is still unclear. We therefore set out
to investigate how patients with SLE degrade DNA from a
range of clinically relevant sources. The aim was to gener-
ate a more comprehensive image of DNA degradation in
SLE and determine what sources of DNA most likely are
involved in disease pathology. In the study, we focused on
DNA sources with known serum nuclease-dependant deg-
radation and used DNA in the form of NETs as well as
chromatin from both primary and secondary necrotic cells
and compared to degradation of purified DNA using a
zymographic approach. The results additionally led us into
some fundamental characterization of the interactions be-
tween DNase-I and serum proteins.
Methods
Patients and sera
A total of 66 SLE patients (5 men and 61 women) with a
median age of 39 years (range 18–75), fulfilling at least
four American College of Rheumatology (ACR) 1982 clas-
sification criteria for SLE [13] were recruited at the Clinic
of Rheumatology, Skåne University Hospital in Lund
(Sweden). The distribution of ACR classification criteria
for SLE is described in Table 1. Disease activity was recorded
using the SLE disease activity index 2000 (SLEDAI-2K) [14].
Sera from 103 healthy volunteers with matched age and sex
were used as controls in the study. All patients and healthy
controls gave informed consent to participate in the study,
which was approved by the local ethics committee (Lund
University) according to the Helsinki declaration.
Degradation of cell chromatin
Jurkat T-cells (ATCC, Manassas, VA, USA) were cul-
tured in Roswell Park Memorial Institute medium
(RPMI) with 10 % foetal calf serum at 37 °C and 5 %
CO2. For experiments, the cells were washed twice, kept
in RPMI and either used directly as live cells alternatively
rendered apoptotic, primary or secondary necrotic. Apop-
tosis was induced by incubation with 1 μM staurosporine
(Sigma-Aldrich, St Louis, MO, USA) at 37 °C for 3 h. Pri-
mary necrosis was induced through incubation in 15 %
EtOH at 37 °C for 1 h and secondary necrosis was inducedwith 20 μM oxaliplatin (Teva, Petach Tikva, Israel) at
37 °C for 48 h as previously described [15]. The cell
states were confirmed with Annexin V (Immunotools,
Friesoythe, Germany) and Via-Probe (BD, San Jose, CA,
USA) staining. For degradation experiments, cells were
washed and incubated with 1.5 % (for degradation of
primary necrotic chromatin) or 3 % (for degradation of
secondary necrotic chromatin) patient sera, pooled nor-
mal human serum (NHS) or fractionated sera for 3 h at
37 °C in 10 mM Tris-HCl, pH 7.5, 50 mM NaCl,
10 mM MgCl2 and 2 mM CaCl2 (DNase buffer). To
analyze DNA degradation, we used Hoechst (Invitrogen,
Waltham, MA, USA) or Via-Probe to detect cellular
double stranded DNA (dsDNA). Loss of signal indicates
nearly complete degradation to small fragments (below
20 bp). DNA content was analyzed in a CyFlow Space
(Partec, Görlitz, Germany) flow cytometer.
Isolation of neutrophils
Neutrophils were isolated from healthy volunteers accord-
ing to a previously published method [16]. Briefly, blood
from healthy volunteers was separated by centrifuga-
tion on a Histopaque 1119 column (Sigma-Aldrich),
the granulocyte-rich fraction was isolated and washed,
and neutrophils were isolated by centrifugation on a Percoll
gradient (65 − 80 %) (GE-healthcare, Fairfield, CT, USA)
and isolated from the intersection of the 70 % and 75 %
layer, washed and resuspended in RPMI with 10 mM
Hepes. Purity of neutrophils (>80 %) was determined by
surface marker expression for anti-CD14 (BD), anti-CD15
and anti-CD16 (both from Immunotools) and defined as
CD16+/CD15+/CD14low.
Generation and degradation of NETs
Freshly isolated neutrophils, 50,000/sample, were seeded
onto a 96-well flat-bottom plate (Nunc, Waltham, MA,
USA) with 20 nM PMA (Sigma-Aldrich) for 4 h at 37 °C
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medium was removed and 10 % patient sera, control sera
or fractionated sera in DNase buffer was added and incu-
bated for 60 minutes at 37 °C. During this time, degraded
NETs were released into solution. Aliquots of the solution
containing NETs were then transferred to PBS with a
final concentration of 2 mM EDTA to stop further deg-
radation and DNA content was quantified using Pico-
Green (Invitrogen). As the internal control, pooled NHS
was used and all samples were compared to the mean of
the internal controls for each individual experiment. All
samples were measured twice, first in duplicates followed
by once in singles and the mean of the two measurements
was used for analysis.
Gel filtration
Serum diluted to 50 % with or without 500,000 cpm =
counts per minute 125I DNase-I (Bioworld, Dublin, OH,
USA), labeled using the chloramine T method, was diluted
in DNase buffer and separated on a Superose 12 column
(GE healthcare) using the ÄKTA system (GE healthcare).
The column was washed with DNase buffer and 0.1 ml
fractions were collected. For assays using radiolabeled
DNase-I, radioactivity was measured in fractions before
stored at −80 °C until further used.
DNase zymogram
Sera from SLE patients and controls were diluted in
DNase buffer to 30 % and loaded onto a native PAGE gel
containing 22 μg/ml denatured calf thymus DNA (Sigma-
Aldrich). As internal controls 30 % NHS was used. Gels
were run at 90 V for 2 h under native non-reducing condi-
tions, washed with dH2O and incubated with 40 mM
Tris–HCl pH 7.5, 8 mM MgCl2, 2 mM CaCl2, 0.02 %
NaN3 at 37 °C for 18 h. After this, ethidium bromide
(EtBr) was added to a final concentration of 1 μg/ml and
gels were incubated at 37 °C for an additional 30 minutes
and analyzed in a ChemiDoc™ MP Imaging System
(BioRad, Hercules, CA, USA). For complex formation
assays, 2.3 μg/ml AF488-labeled DNase-I was incu-
bated with 5–200 μg/ml actin from rabbit skeletal
muscle (Sigma-Aldrich) or 150–200 μg/ml Gc-globulin
(Sigma-Aldrich) in 10 % NHS or heat-inactivated NHS
(Hi-NHS) and run as above.
Statistical analyses
For comparison of chromatin degradation between two
groups the Mann-Whitney test was used. For comparison
between multiple experimental parameters two-way ana-
lysis of variance (ANOVA) was used followed by Bonferroni
post hoc test in GraphPad Prism 5 (GraphPad, La Jolla,
CA, USA). Association with disease manifestation was
tested using Pearson’s chi-square (χ2) test. For principal
component analysis, cluster analysis and analysis ofassociation with disease manifestation was performed using
JMP 11 (SAS, Cary, NC, USA).
Results
Chromatin degradation in primary and secondary necrotic
cells is dependent on serum nucleases
To analyze degradation of chromatin in dying cells we
induced different forms of cell death and analyzed cell
states using Annexin V and Via-Probe (Fig. 1a-d). Annexin
V detects the externalization of phosphatidylserine, which
is initiated early in dying cells, whereas Via-Probe binds
DNA in cells that have lost membrane integrity during
later stages of cell death. Live cells are hence double nega-
tive (Fig. 1a), apoptotic cells are only positive for Annexin
V (Fig. 1b), primary necrotic cells are double positive
(Fig. 1c) and secondary necrotic cells display a mixed
population (Fig. 1d). To compare the need for active
serum nuclease for degradation of chromatin in these
forms of cell death, cellular DNA content was measured
by flow cytometry after incubation with either NHS or
Hi-NHS. As expected, no degradation of chromatin was
observed when live cells were incubated with NHS or
Hi-NHS (Fig. 1e and i). While the majority of apoptotic
cells endogenously degraded chromatin, there was no
additional degradation by NHS compared to Hi-NHS
(Fig. 1f and j). Unlike apoptotic cells, no endogenous
nuclease activity appeared to be activated in primary
necrotic cells and chromatin was only degraded when
incubated with NHS but not with Hi-NHS (Fig. 1g and k).
We also observed endogenous degradation in secondary
necrotic cells, however there was also serum-dependent
degradation (Fig. 1h and l). Thus, we can conclude that
apoptotic chromatin is initially degraded by endogenous
nucleases, primary necrotic cells by serum nucleases while
secondary necrotic cells are degraded by both endogenous
and serum nucleases. As our aim was to investigate the
role of serum nucleases in SLE, we focused the study on
the degradation of primary and secondary necrotic cells.
Degradation of chromatin from multiple sources is
decreased in SLE
The ability of sera from 66 patients with SLE to degrade
primary and secondary necrotic chromatin as well as
NETs (the latter data were published previously elsewhere
[17] but are used here for comparison), were investigated
and compared to healthy controls. Throughout the study,
we have defined low degradation as an activity of more
than 2 SD below the mean of the healthy controls (Fig. 2,
dotted line). In our titration experiments (Fig. 1) we no-
ticed that degradation of secondary necrotic cells requires
a higher serum concentration, therefore 3 % serum was
used in this experiments compared to 1.5 % for degrad-
ation of primary necrotic cells. As previously shown, a
subgroup of 30 % of serum samples from patients with
Fig. 1 Serum nucleases degrade chromatin in primary and secondary necrotic cells. Annexin V and Via-Probe was used to define live (a), apoptotic
(b) primary necrotic (Prim-Nec) (c) and secondary necrotic (Sec-Nec) (d) cell states in Jurkat T-cells. The degradation of chromatin in live
(e), apoptotic (f) primary (g) and secondary necrotic (h) cellular DNA content was determined after incubating cells with normal human serum
(NHS) or heat-inactivated normal human serum (Hi-NHS). Cells with subnormal DNA content as indicated by the vertical gate were quantified
for different serum concentrations and displayed as percentage of the total cell population (i-l). a-h Representative histograms of three independent
experiments using 3 % serum in e-h. i-l Mean ± SD of e-h at varying serum concentrations. Significance of difference was calculated using two-way
analysis of variance with the Bonferroni post hoc test; ***p <0.001
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group of 62 % of SLE patients had decreased ability to de-
grade primary necrotic chromatin (Fig. 2b) and very few
patients (14 %) were unable to degrade secondary necrotic
cells (Fig. 2c). To determine how degradation of the chro-
matin sources correlated, we used principal component
analysis. NET degradation was more closely correlated to
degradation of secondary necrotic chromatin compared toprimary necrotic chromatin (Fig. 2d). Next we investigated
the role of serum nucleases for NETs and chromatin
degradation.
Degradation of chromatin from necrotic cells and NETs is
carried out by DNase-I in complex with serum protein(s)
It has previously been established that DNase-I is the
major nuclease that degrades NETs [7] and necrotic
Fig. 2 Sera from patients with systemic lupus erythematosus (SLE) had decreased ability to degrade multiple forms of chromatin. a-c Sera from 66
patients with SLE were used to determine degradation of neutrophil extracellular trap (NET) (a), primary (Prim-Nec) (b), and secondary (Sec-Nec)
necrotic cell chromatin (c) in comparison to controls (Healthy ctrl) (a, n = 77; b, n = 50; c, n = 66). A cutoff below 2 SD below the mean degradation in
the control group defined patients with low degrading ability and is indicated by the dotted line. d Principal component analysis for correlation
revealed that degradation of secondary necrotic chromatin and NETs co-correlated. a-c Mean of three independent experiments with an average SD
of 5 %. Significance of difference in (a-c) was calculated using the Mann-Whitney test; ***p <0.001; *p <0.05. NHS normal human serum
Fig. 3 DNase-I binds to serum protein(s) but remains active. a Normal human serum (NHS) separated by size using gel filtration was tested for
neutrophil extracellular trap (NET) degrading activity (dashed blue line, right y-axis) and primary necrotic chromatin degrading activity (green line, left y-axis).
Activity was confined to one peak. Serum with 125I-labeled DNase-I was used to determine if degradation corresponded to DNase-I activity. The 125I
DNase-I incubated with NHS eluted in two peaks as judged by 125I radiation (insert) indicating free DNase-I and DNase-I bound to a serum protein(s) or
forming multimers. Proteins eluted in both peaks contained NET degradation activity (solid blue line, right y-axis). b AF488-labeled DNase-I was incubated
with increasing concentrations of actin, or Gc globulin as negative control, in NHS or heat-inactivated NHS (Hi-NHS) and subjected to native
DNA zymogram. At increasing concentrations of actin, DNase-I (green) shifted to a larger/less charged state although it remained active as
judged by activity staining (red). a Representative data of two independent experiments. b Representative gel out of three independent experiments.
Prim-Nec primary necrotic chromatin, cpm = counts per minute
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activity we used size-separating gel filtration chromatog-
raphy on NHS and used the size-fractionated serum to
degrade NETs and chromatin from primary necrotic cells.
We observed that the same fractions (around 13 ml)
degraded both NETs (Fig. 3a, blue dotted line) and nec-
rotic chromatin (Fig. 3a, green line). To confirm that
this size corresponded to DNase-I we spiked NHS with
radiolabeled DNase-I. Interestingly, we observed that
radioactivity was eluted in two peaks (Fig. 3a, insert)
and that eluted proteins of both peaks were able to
degrade NETs (Fig. 3a, blue line). The second peak
(around 16 ml) corresponded to the elution volume of
monomeric DNase-I (data not shown). This indicates
that active DNase-I is either in complex with a serum
protein or in a multimeric form in serum. DNase-I binds to
monomeric actin in serum, which is known as a strong
DNase-I inhibitor [18, 19]. The results from our gel-
filtration assay, however, suggest that DNase-I remains
active. To test if this excludes actin as the DNase-I bind-
ing protein, we used a zymographic approach to test if
actin indeed inactivates DNase-I in our setup. Using a na-
tive PAGE containing DNA and fluorescently labeled
DNase-I to trace the protein and EtBr to detect loss ofFig. 4 DNase-I complex activity does not differ in patients with systemic lu
serum (NHS), heat-inactivated NHS (Hi-NHS) from SLE patients (n = 66) or sera
Nuclease activity was detected as lack of ethidium bromide (EtBr) staining to
a Representative zymogram for sera from two controls and two SLE pat
and bound DNase-I. b DNase-I complex activity was quantified and compared
for particular patient groups with low neutrophil extracellular trap (NET) degrad
necrotic chromatin degradation (e). Significance of difference was calculated u
necrotic chromatin, Sec-Nec secondary necrotic chromatin, std. standardDNA in particular areas as a result of nuclease activity. By
adding globular actin to serum spiked with DNase-I we
observed that DNase-I bound to actin in a concentration-
dependent manner (Fig. 3b). We also observed, as judged
by the nuclease activity, that the DNase-I-actin complex
remained active. As a negative control, no complex for-
mation was observed using Gc-globulin, which binds
the DNase-actin complex through actin [20]. Further,
the actin-DNase-I complex also formed and remained
active in Hi-NHS.
DNase-I complex activity is not decreased in SLE patients
After establishing that serum DNase-I is active as a pro-
tein complex in serum, we used the same zymographic
approach to investigate if the activity of the complex is
altered in SLE patients. In NHS we observed two bands
of nuclease activity (Fig. 4a). As expected, these did not
correlate with free DNase-I but resembled the bands in-
duced by actin (Fig. 3b; top band represents the DNase-
I-actin complex and the second a transition/unknown
state). As our data suggest that the DNase-I-actin serum
complex degrades NETs and necrotic chromatin, we
used the top band to analyze serum nuclease activity.
We discovered a large variation in activity betweenpus erythematosus (SLE) compared to healthy controls. Normal human
from controls (ctrl) (n = 62) were separated on native DNA zymograms.
DNA (dark bands). Heating efficiently inhibited all nuclease activity.
ients with NHS as internal control and NHS + DNase-I to indicate free
between SLE patients and controls. c-e Activity of the same band is shown
ation (c), low primary necrotic chromatin degradation (d) or low secondary
sing the Mann-Whitney test (b-e); n.s. not significant. Prim-Nec primary
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and SLE patients with no significant difference between
the two groups (Fig. 4a, b). Further, no difference was
observed between SLE patients who did not degrade
NETs, or primary or secondary necrotic chromatin
(Fig. 4c-e). Together this demonstrates that although a
large proportion of the patients in this SLE cohort have a
decreased ability to degrade chromatin from particular
cellular sources, when analyzed on pure and denatured
DNA the activity of the serum DNase-I complex is not
significantly decreased compared to healthy controls.
Decreased degradation is associated with disease
manifestation
We and others have previously observed that decreased
ability to degrade NETs is associated with elevated






Organic brain syndrome 0 0/0
Visual disturbance 1 0/2.2
Lupus headache 0 0/0











Mucosal ulcers 8 15/11
Pleuritis 3 5/4.4
Pericarditis 0 0/0
Low complement 23 35/35




Clinical manifestations during the time of sample collection were divided into grou
primary and secondary necrotic chromatin. Total patients with manifestation are in
patients with low-versus-normal degrading ability are indicated and percent of pati
manifestation. Significance of differences were calculated using Pearson’s χ2 test: *pglomerulonephritis [6, 7, 17]. To determine if this asso-
ciation is NET-specific or related to a general decrease
in ability to degrade chromatin, we analyzed the distri-
bution of SLEDAI qualifying manifestations in the
groups with low and normal ability to degrade NETs,
primary and secondary necrotic chromatin (Table 2).
As previously established, decreased ability to degrade
NETs was associated with glomerulonephritis and DNA
antibodies. A similar pattern was also observed for pa-
tients who did not degrade secondary necrotic chroma-
tin. However, patients who did not degrade primary
necrotic chromatin only had an increased incidence of
fever. To further isolate manifestations associated with a
general decrease in DNA degradation in SLE we used
cluster analysis based on the degradation data to classify
patient subsets (Fig. 5a). The analysis rendered 3 clusters
with cluster 1 including patients with a decrease insed ability to degrade chromatin from multiple sources
Primary necrotic chromatin Secondary necrotic chromatin
n = 41/25 n = 9/56
























ps according to their ability to degrade neutrophil extracellular traps (NETs),
dicated in the first column. For each source of DNA the total number of
ents with low-versus-normal degrading ability are indicated for each respective
<0.05: and ***p <0.001; increased proportions in bold text
Fig. 5 Degradation generates three distinct clusters of patients with distinct clinical manifestations. a Cluster analysis of degradation of neutrophil
extracellular traps (NETs), primary necrotic and secondary necrotic chromatin displayed as red (normal) to blue (low) in the respective columns,
one patient per row (n = 65). b DNase activity in the three clusters with no significant differences between the groups. c Proportions of patients
with indicated systemic lupus erythematosus disease activity index manifestation in each cluster (only manifestations affecting >10 % of patients
were included). Significance of differences was calculated using Pearson’s χ2 test; ***p <0.001; **p <0.01; *p <0.05. Prim-Nec primary necrotic
chromatin, deg degradation, std. standard
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ter 2 included patients with mostly normal degradation,
whereas cluster 3 included almost exclusively patients
with a decreased ability to degrade all tested forms of
DNA. Interestingly and as expected from previous re-
sults, we found that nuclease activity did not differ be-
tween the three clusters (Fig. 5b). When analyzing the
presentation of clinical manifestations in the three clus-
ters we found that manifestations associated with
kidney disease as well as dsDNA antibodies were
significantly more common in cluster 3 (Fig. 5c), sug-
gesting these manifestations were associated with chro-
matin degradation independent of DNA source.
Discussion
For unknown reasons the ability to degrade DNA is de-
creased in a proportion of patients with SLE. In this report
we have systematically investigated the ability of sera fromSLE patients to degrade DNA from multiple clinically
relevant sources of DNA. We have focused the study
on degradation of DNA sources that are dependent on
serum nucleases as determined in previous reports [11, 15]
and as shown in Fig. 1. Interestingly, the study reveals that
the majority of patients with SLE (61 %, n = 40) exhibit
decreased ability to degrade chromatin from either NETs,
primary or secondary necrotic cells by serum. As there are
multiple nucleases expressed in different tissues and
cellular locations [21], it is tempting to speculate that
studies of other means of degradation such as endogenous
degradation of apoptotic chromatin by caspase-activated
DNase [22] as well as other intracellular DNases such as
TREX1 [23, 24] and DNase-gamma [25] may expand this
group further and should be addressed in future studies.
Although there was relatively poor correlation between
decreased degradation of different types of chromatin, we
did identify a subset of patients with a distinct clinical
Leffler et al. Arthritis Research & Therapy  (2015) 17:205 Page 9 of 10phenotype associated with a general decrease in NET/
chromatin degradation. Patients in cluster 1 mainly
displayed a decreased degradation of primary necrotic
chromatin, which points in a direction of a separate
mechanism of degradation and aligns with previous re-
ports describing cofactor-dependent degradation of the
highly condensed chromatin from primary necrotic cells
that require decondensation before efficient degradation.
Presence of anti-DNA antibodies appears to prevent deg-
radation of the decondensed NETs [7] and possibly also
chromatin from secondary necrotic cells, which aligns
with the clinical associations in cluster 3. Additionally,
there are also reports of protein-DNA complexes, origin-
ating from NETs, being less efficiently degraded in SLE
[26] which require further investigation in relation to
other sources of DNA. To address the decreased ability to
degrade primary necrotic chromatin in cluster 1, we used
western blot to analyze protein levels of some DNase-I co-
factors, such as C1q [8] and factor VII-activating protease
[10]. We did observe a trend towards lower levels in par-
ticular of factor VII-activating protease in cluster 1, how-
ever this did not reach statistical significance (data not
shown). Most likely, a more systematic approach employ-
ing more sensitive methods would be required to properly
address this issue. The data in this study do suggest such
study should focus on patients in cluster 1.
Mice that lack DNase-I develop SLE-like disease [27]
and nephritis in mice and humans is also associated with
a decrease in DNase-I expression [28]. Multiple studies
have found decreased nuclease activity in patients with
SLE [4, 29, 30]. However, these studies measured total
nuclease activity using radial diffusion or oligonucleotide
immune assays that neither separate forms of serum nu-
cleases nor do they take into account the presence of
potential nuclease inhibitors in serum. By using a zymo-
graphic approach, we separated serum proteins based on
charge and therefore reduced the likelihood of interfer-
ence with inhibitors that are not strongly bound to
DNase-I. It is interesting to note that in this setting
there was no difference in DNase-I activity between
healthy controls and SLE patients, at least not in the in-
vestigated cohort. Even though DNase-I mutations in
SLE are rare [31], investigation of such mutations or
transcription forms in individuals with low activity may
be of interest. The data do however suggest that it is not
the DNase-I activity per se that is affected in these SLE
patients but rather DNase-I is prevented from degrading
chromatin, potentially by sterically blocking access for
DNase-I by dsDNA antibodies generated during the dis-
ease. Additionally, we cannot rule out that patients with
low ability to degrade primary necrotic chromatin pro-
duce lower levels of cofactors. Together, the data hence
suggest that the decreased degradation observed in SLE
is not a predisposing factor but rather a consequence ofthe autoimmune response most likely further fuelling
disease pathology such as kidney disease. This aligns
well with the pathology of the DNase−/− mouse [32]. We
recently found that an inability of SLE patients to de-
grade NETs is, in the majority of cases, not permanent
but usually recovers within a period of 6 months indicat-
ing that this is a dynamic process that correlates with
disease activity and levels of nuclear autoantibodies [17].
A pharmacological study in rats first observed that
DNase-I binds a serum protein, which most likely is globu-
lar actin [18]. In the present study we can demonstrate that
this complex is surprisingly active and appears to be the
major form of DNase-I in the serum of healthy individuals.
Inhibition of the actin-DNase-I complex is thought to be
dependent on ATP, which was not included in our experi-
mental setup. However when we used an ATP analog to
confirm inhibition, disassociation of the complex occurred
most likely due to polymerization of actin (data not
shown). It is possible that this does not occur in vivo
where there are actin depolymerizing factors and ATP
stabilizing factors. Recently, this issue was addressed
using gelsolin to prevent actin polymerization [33]. In-
triguingly, as extracellular ATP is a marker of inflamma-
tion it is tempting to speculate that this may prevent
NETs from being degraded at a site of inflammation and
infection.
Conclusions
The current study highlights the importance of the abil-
ity to properly degrade chromatin from multiple DNA
sources in SLE and how such sources may influence clin-
ical outcomes for the patient. We have identified a subset
of patients with SLE with a decreased ability to degrade all
forms of DNA/chromatin and this group poses a prime
target for therapies aiming to increase degradation.
However, our study also highlights the complex interac-
tions of DNase-I and serum proteins that are important
to consider in the future for the development of effect-
ive DNase-I therapy.
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